Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1994 Apr;47(4):300–302. doi: 10.1136/jcp.47.4.300

IgM ganglioside GM1 antibodies in patients with autoimmune disease or neuropathy, and controls.

A S Bansal 1, B Abdul-Karim 1, R A Malik 1, P Goulding 1, R S Pumphrey 1, A J Boulton 1, P L Holt 1, P B Wilson 1
PMCID: PMC501930  PMID: 8027366

Abstract

AIMS--To compare the titre of anti-ganglioside antibodies (AGA) to GM1 ganglioside in patients with central and peripheral neurological disease and pure motor and sensorimotor neuropathy, in patients with classic autoimmune diseases, and controls. METHODS--AGA to GM1 were measured using an enzyme linked immunosorbent assay (ELISA) technique, highly purified bovine GM1 ganglioside, and sequential dilution of control and test sera. Antibody titre was calculated using the optical density readings of three consecutive serum dilutions multiplied by the dilution factor. RESULTS--A considerable overlap was evident in the titre of AGA to GM1 in control and test sera. High antibody titres were most frequent in patients with multifocal motor neuropathy with conduction block (MMNCB). Low AGA titre were observed in several patient groups. Compared with the controls, the median titre of AGA to GM1 was significantly higher in patients with multiple sclerosis, rheumatoid arthritis, primary Sjögren's syndrome and systemic lupus erythematosus. In contrast, the median titre in patients with diabetic peripheral neuropathy, motor neurone disease, sensorimotor neuropathy and chronic inflammatory demyelinating polyneuropathy was no different from that in normal control subjects. CONCLUSIONS--Estimation of AGA to GM1 may be helpful in the diagnosis of MMNCB in patients with a pure motor neuropathy but in few other conditions. Low titre AGA to GM1 are evident in several autoimmune conditions. The pathogenetic importance of AGA to GM1 in patients with neuropathy is not clear.

Full text

PDF
300

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams D., Kuntzer T., Burger D., Chofflon M., Magistris M. R., Regli F., Steck A. J. Predictive value of anti-GM1 ganglioside antibodies in neuromuscular diseases: a study of 180 sera. J Neuroimmunol. 1991 Jun;32(3):223–230. doi: 10.1016/0165-5728(91)90192-a. [DOI] [PubMed] [Google Scholar]
  2. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
  3. Baba H., Daune G. C., Ilyas A. A., Pestronk A., Cornblath D. R., Chaudhry V., Griffin J. W., Quarles R. H. Anti-GM1 ganglioside antibodies with differing fine specificities in patients with multifocal motor neuropathy. J Neuroimmunol. 1989 Dec;25(2-3):143–150. doi: 10.1016/0165-5728(89)90131-8. [DOI] [PubMed] [Google Scholar]
  4. Corbo M., Quattrini A., Latov N., Hays A. P. Localization of GM1 and Gal(beta 1-3)GalNAc antigenic determinants in peripheral nerve. Neurology. 1993 Apr;43(4):809–814. doi: 10.1212/wnl.43.4.809. [DOI] [PubMed] [Google Scholar]
  5. Endo T., Scott D. D., Stewart S. S., Kundu S. K., Marcus D. M. Antibodies to glycosphingolipids in patients with multiple sclerosis and SLE. J Immunol. 1984 Apr;132(4):1793–1797. [PubMed] [Google Scholar]
  6. Fox R. I., Robinson C., Curd J., Michelson P., Bone R., Howell F. V. First international symposium on Sjögren's syndrome: suggested criteria for classification. Scand J Rheumatol Suppl. 1986;61:28–30. [PubMed] [Google Scholar]
  7. Hirano T., Hashimoto H., Shiokawa Y., Iwamori M., Nagai Y., Kasai M., Ochiai Y., Okumura K. Antiglycolipid autoantibody detected in the sera from systemic lupus erythematosus patients. J Clin Invest. 1980 Dec;66(6):1437–1440. doi: 10.1172/JCI109999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Latov N., Hays A. P., Donofrio P. D., Liao J., Ito H., McGinnis S., Konstadoulakis M., Freddo L., Shy M. E., Manoussos K. Monoclonal IgM with unique specificity to gangliosides GM1 and GD1b and to lacto-N-tetraose associated with human motor neuron disease. Neurology. 1988 May;38(5):763–768. doi: 10.1212/wnl.38.5.763. [DOI] [PubMed] [Google Scholar]
  9. Malik R. A., Newrick P. G., Sharma A. K., Jennings A., Ah-See A. K., Mayhew T. M., Jakubowski J., Boulton A. J., Ward J. D. Microangiopathy in human diabetic neuropathy: relationship between capillary abnormalities and the severity of neuropathy. Diabetologia. 1989 Feb;32(2):92–102. doi: 10.1007/BF00505180. [DOI] [PubMed] [Google Scholar]
  10. Pestronk A., Adams R. N., Clawson L., Cornblath D., Kuncl R. W., Griffin D., Drachman D. B. Serum antibodies to GM1 ganglioside in amyotrophic lateral sclerosis. Neurology. 1988 Sep;38(9):1457–1461. doi: 10.1212/wnl.38.9.1457. [DOI] [PubMed] [Google Scholar]
  11. Pestronk A., Chaudhry V., Feldman E. L., Griffin J. W., Cornblath D. R., Denys E. H., Glasberg M., Kuncl R. W., Olney R. K., Yee W. C. Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies. Ann Neurol. 1990 Mar;27(3):316–326. doi: 10.1002/ana.410270314. [DOI] [PubMed] [Google Scholar]
  12. Pestronk A., Cornblath D. R., Ilyas A. A., Baba H., Quarles R. H., Griffin J. W., Alderson K., Adams R. N. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol. 1988 Jul;24(1):73–78. doi: 10.1002/ana.410240113. [DOI] [PubMed] [Google Scholar]
  13. Pestronk A. Invited review: motor neuropathies, motor neuron disorders, and antiglycolipid antibodies. Muscle Nerve. 1991 Oct;14(10):927–936. doi: 10.1002/mus.880141002. [DOI] [PubMed] [Google Scholar]
  14. Raveche E. S. Possible immunoregulatory role for CD5 + B cells. Clin Immunol Immunopathol. 1990 Aug;56(2):135–150. doi: 10.1016/0090-1229(90)90136-e. [DOI] [PubMed] [Google Scholar]
  15. Sadiq S. A., Thomas F. P., Kilidireas K., Protopsaltis S., Hays A. P., Lee K. W., Romas S. N., Kumar N., van den Berg L., Santoro M. The spectrum of neurologic disease associated with anti-GM1 antibodies. Neurology. 1990 Jul;40(7):1067–1072. doi: 10.1212/wnl.40.7.1067. [DOI] [PubMed] [Google Scholar]
  16. Santoro M., Uncini A., Corbo M., Staugaitis S. M., Thomas F. P., Hays A. P., Latov N. Experimental conduction block induced by serum from a patient with anti-GM1 antibodies. Ann Neurol. 1992 Apr;31(4):385–390. doi: 10.1002/ana.410310407. [DOI] [PubMed] [Google Scholar]
  17. Shy M. E., Evans V. A., Lublin F. D., Knobler R. L., Heiman-Patterson T., Tahmoush A. J., Parry G., Schick P., DeRyk T. G. Antibodies to GM1 and GD1b in patients with motor neuron disease without plasma cell dyscrasia. Ann Neurol. 1989 May;25(5):511–513. doi: 10.1002/ana.410250517. [DOI] [PubMed] [Google Scholar]
  18. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  19. Weller M., Stevens A., Sommer N., Dichgans J., Kappler B., Wiethölter H. Ganglioside antibodies: a lack of diagnostic specificity and clinical utility? J Neurol. 1992 Oct;239(8):455–459. doi: 10.1007/BF00856811. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES